Glutamine supplementation for cystic fibrosis

Submission date	Recruitment status	[X] Prospectively registered
22/11/2007	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
21/12/2007	Completed	[X] Results
Last Edited	Condition category	Individual participant data
05/06/2017	Nutritional, Metabolic, Endocrine	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Andrew Fogarty

Contact details

Division of Epidemiology and Public Health Clinical Science Building Nottingham City Hospital Nottingham United Kingdom NG5 1PB +44 115 823 1713 andrew.fogarty@nottingham.ac.uk

Additional identifiers

EudraCT/CTIS number 2007-006204-37

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

2007 version 3

Study information

Scientific Title

Glutamine supplementation for cystic fibrosis

Study objectives

Will glutamine supplementation for eight weeks improve sputum and blood inflammatory markers of cystic fibrosis activity?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Nottingham Research Ethics Committee 2, 09/07/2008, ref: 08/H0408/26

Amendment approved 28/07/2008.

Study design

Parallel group placebo controlled randomised trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cystic fibrosis

Interventions

- 1. Glutamine 21 g/day
- 2. Placebo

Treatment will continue for eight weeks for both. Follow up will occur for this entire period and a telephone call will be made 4 weeks later.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Glutamine supplementation

Primary outcome measure

Change in inflammatory markers in induced sputum, measured at baseline and after eight weeks.

Secondary outcome measures

- 1. FEV1
- 2. Serum C-reactive protein (CRP)
- 3. Infectious load of Pseudomonas
- 4. Systemic blood neutrophil activity
- 5. Jensen clinical score

All outcomes measured at baseline and after eight weeks.

Overall study start date

01/01/2008

Completion date

31/12/2009

Eligibility

Key inclusion criteria

- 1. Over 14 years old, male and female
- 2. Forced expiratory volume in one second (FEV1) greater than 40% predicted or receive regular nebulised saline treatment
- 3. Colonisation with Pseudomonas

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

44

Key exclusion criteria

- 1. Current pregnancy or breastfeeding
- 2. Recent pulmonary exacerbation in past month
- 3. Lung transplant
- 4. Recently diagnosed or uncontrolled diabetes
- 5. Cirrhosis or severe liver failure
- 6. Initiation of new pulmonary therapies in the past month

Date of first enrolment

01/01/2008

Date of final enrolment 31/12/2009

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Division of Epidemiology and Public Health
Nottingham
United Kingdom
NG5 1PB

Sponsor information

Organisation

University of Nottingham (UK)

Sponsor details

University Park Nottingham England United Kingdom NG5 1PB

Sponsor type

University/education

Website

http://www.nottingham.ac.uk

ROR

https://ror.org/01ee9ar58

Funder(s)

Funder type

Research organisation

Funder Name

Cystic Fibrosis Foundation (USA)

Alternative Name(s)

CF Foundation, CFF

Funding Body Type

Government organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United States of America

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2016		Yes	No